Alnylam Pharma (ALNY) Ownership - Who Owns Alnylam Pharma?

1,408 Followers

Alnylam Pharma (ALNY) Ownership Overview

0.25% Insiders

43.78% Mutual Funds

1.11% Other Institutional Investors

21.98% ETFs

32.89% Public Companies and

Individual Investors

The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 66.86% of the company’s stock is owned by Institutional Investors, 0.25% is owned by Insiders, and 32.89% is owned by Public Companies and Individual Investors.

The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 44.89% of the company’s stock is owned by Institutional Investors, 0.25% is owned by Insiders, and 21.98% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date	Name	Activity	Value
Apr 07, 2026	Melissa Mclaughlin	xxxxxxxxxxxxx	$519014
Mar 06, 2026	Pushkal Garg	xxxxxxxxxxxxx	$745984
Mar 06, 2026	Yvonne Greenstreet	xxxxxxxxxxxxx	$947581
Mar 06, 2026	Jeffrey V. Poulton	xxxxxxxxxxxxx	$797351

Show More Insider Trading Activity >

Recent Hedge Fund Trading Activity

Date	Firm	Activity	Value
Dec 31, 2023	Dodge & Cox	xxxxxxxxxxxxx	$781149625
Dec 31, 2023	Bridgewater Associates, Lp	xxxxxxxxxxxxx	$34045600
Dec 31, 2023	Hussman Strategic Advisors Inc	xxxxxxxxxxxxx	$2505195
Dec 31, 2023	Driehaus Capital Management Llc	xxxxxxxxxxxxx	$27747222

Show More Hedge Fund Trading Activity >

Top Shareholders

# of Shares	Type	% Holding	Value
12,169,606	Institution	9.12%	3,665,363,631
11,242,175	Institution	8.43%	3,386,030,688
8,024,520	Institution	6.01%	2,416,905,179
5,726,003	Institution	4.29%	1,724,614,844
4,159,985	Institution	3.12%	1,252,945,882
3,744,659	Institution	2.81%	1,127,853,844
2,436,710	Institution	1.83%	733,912,685
2,392,493	Institution	1.79%	720,594,967
2,246,395	Institution	1.68%	676,591,710
2,218,165	Institution	1.66%	668,089,116

Top Mutual Fund Holders

# of Shares	Type	% Holding	Value
11,242,175	Institution	8.43%	3,386,030,688
8,024,520	Institution	6.01%	2,416,905,179
3,744,659	Institution	2.81%	1,127,853,844
2,436,710	Institution	1.83%	733,912,685
2,392,493	Institution	1.79%	720,594,967
2,246,395	Institution	1.68%	676,591,710
2,218,165	Institution	1.66%	668,089,116
2,051,779	Institution	1.54%	617,975,317
1,604,154	Institution	1.20%	483,155,143
1,478,741	Institution	1.11%	445,382,002

Top ETF Holders

Holder	# of Shares	Type	% Holding	Value
Vanguard Total Stock Market ETF	4,217,053	Institution	3.16%	1,395,296,326
Vanguard Mid-Cap ETF	2,864,993	Institution	2.15%	947,940,234
Invesco QQQ Trust	2,817,725	Institution	2.11%	848,670,593
Vanguard Growth ETF	1,564,640	Institution	1.17%	517,692,437
Vanguard Extended Market ETF	1,482,298	Institution	1.11%	490,447,939
Vanguard Mid-Cap Growth ETF	1,008,744	Institution	0.76%	333,763,127
iShares Biotechnology ETF	969,462	Institution	0.73%	292,884,165
iShares Russell Mid-Cap Growth ETF	838,926	Institution	0.63%	252,676,122
Capital Group Growth ETF	597,394	Institution	0.45%	179,929,099
Invesco NASDAQ 100 ETF	533,393	Institution	0.40%	160,652,638

FAQ

Who Owns Alnylam Pharmaceuticals (ALNY)?

According to the latest TipRanks data, approximately 1.11% of the company's stock is held by institutional investors, 0.25% is held by insiders, and 32.89% is held by retail investors.

What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors?

According to the latest TipRanks data, approximately 1.11% of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors.

What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors?

According to the latest TipRanks data, approximately 32.89% of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors.

Who owns the most shares of Alnylam Pharmaceuticals (ALNY)?

Vanguard owns the most shares of Alnylam Pharmaceuticals (ALNY).

What is the significance of the ownership structure for a publicly traded company?

The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.